Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 11 , ISSUE 1 ( January-March, 2022 ) > List of Articles


Aviptadil- Class Effect of a Synthetic Vasoactive Intestinal Peptide as a Treatment Option in COVID-19 Patients with Severe Respiratory Failure

Dwaipayan Sarathi Chakraborty, Shouvik Choudhury, Sandeep Lahiry

Keywords : Interim, pandemic, SARS COV-2, synthetic, vasoactive intestinal peptide

Citation Information : Chakraborty DS, Choudhury S, Lahiry S. Aviptadil- Class Effect of a Synthetic Vasoactive Intestinal Peptide as a Treatment Option in COVID-19 Patients with Severe Respiratory Failure. Indian J Respir Care 2022; 11 (1):5-10.

DOI: 10.4103/ijrc.ijrc_127_21

License: CC BY-NC-SA 4.0

Published Online: 06-12-2022

Copyright Statement:  Copyright © 2022; Indian Journal of Respiratory Care.


The whole world has witnessed an unimaginable, unforgettable medical disaster in the last 1 and ½ years in form of the demise of innumerable people due to the current pandemic of SARS COV-2. Despite several efforts to develop strong evidence-based effective and safe treatment regimens, the options remain very limited, to date. Vasoactive intestinal peptide (VIP) discovered as a gut peptide hormone in earlier days was found to have diversified physiological action with specific features of lung protection-related activities. It has a unique feature of binding to angiotensin-converting enzyme (ACE) receptor of Type II alveolar cell to which the COVID 19 virus also binds. Aviptadil as a synthetic VIP has already been proved to be an effective option in the treatment of severe respiratory failure due to sepsis and other related lung injuries. Interim analysis results of this drug use in respiratory failures caused by SARS COV-2 has evolved a new hope in regards to safety and efficacy. Final results from recently completed as well as currently, ongoing trials will clarify the class effect of this drug in the treatment of COVID 19 in the days to come.

  1. Chacko J, Unais M. Pharmacologic treatment of COVID-19: Evidence-based update. Indian J Respir Care 2021;10 Suppl S1:34-8.
  2. Heustess AM, Allard MA, Thompson DK, Fasinu PS. Clinical management of COVID-19: A review of pharmacological treatment options. Pharmaceuticals (Basel) 2021;14:520.
  3. Said SI, Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature 1970;225:863-4.
  4. Li L, Hua S, Shaojie Y, Yue S, Luo Z. Vasoactive intestinal polypeptide induces surfactant protein A expression in ATII cells through activation of PKC/c-Fos pathway. Peptides 2010;31:2016-51.
  5. Mossel EC, Wang J, Jeffers S, Edeen KE, Wang S, Cosgrove GP, et al. SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. Virology 2008;372:127-35.
  6. Tang H, Welton A, Ganea D. Neuropeptide regulation of cytokine expression: Effects of VIP and Ro 25-1553. J Interferon Cytokine Res 1995;15:993-1003.
  7. Voice JK, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell targeted type II VIP receptor transgenic mice. J Immunol 2003;170:308-14.
  8. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: A new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007;13:241-51.
  9. Delgado M, Martinez C, Pozo D, Calvo JR, Leceta J, Ganea D, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J Immunol 1999;162:1200-5.
  10. Berisha HI, Bratut M, Bangale Y, Colasurdo G, Paul S, Said SI. New evidence for transmitter role of VIP in the airways: Impaired relaxation by a catalytic antibody. Pulm Pharmacol Ther 2002;15:121-7.
  11. Sharma V, Delgado M, Ganea D. Granzyme B, a new player in activation-induced cell death is downregulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. J Immunol 2006;176:97-110.
  12. Said SI. Vasoactive intestinal peptide in the lung. Ann NY Acad Sci 1988;527:450-64.
  13. Hasaneen NA, Foda HD, Said SI. Nitric oxide and vasoactive intestinal peptide as co-transmitters of airway smooth-muscle relaxation: Analysis in neuronal nitric oxide synthase knockout mice. Chest 2003;124:1067-72.
  14. Saga T, Said SI. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians 1984;97:304-10.
  15. Nagahiro I, Yano M, Boasquevisque CH, Fujino S, Cooper JD, Patterson GA. Vasoactive intestinal peptide ameliorates reperfusion injury in rat lung transplantation. J Heart Lung Transplant 1998;17:617-21.
  16. Virgolini I, Kurtaran A, Raderer M, Leimer M, Angelberger P, Havlik E, et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 1995;36:1732-9.
  17. Mathioudakis A, Chatzimavridou-Grigoriadou V, Evangelopoulou E, Mathioudakis G. Vasoactive intestinal Peptide inhaled agonists: Potential role in respiratory therapeutics. Hippokratia 2013;17:12-6.
  18. Berisha H, Foda H, Sakakibara H, Trotz M, Pakbaz H, Said SI. Vasoactive intestinal peptide prevents lung injury due to xanthine/xanthine oxidase. Am J Physiol 1990;259:L151-5.
  19. Li L, She H, Yue SJ, Qin XQ, Guan CX, Liu HJ, et al. Role of c-fos gene in vasoactive intestinal peptide promoted synthesis of pulmonary surfactant phospholipids. Regul Pept 2007;140:117-24.
  20. Delgado M, Munoz-Elias EJ, Kan Y, Gozes I, Fridkin M, Brenneman DE, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. J Biol Chem 1998;273:31427-36.
  21. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J 2020;55:2000607.
  22. Onoue S, Ohmori Y, Endo K, Yamada S, Kimura R, Yajima T. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells. Eur J Biochem 2004;271:1757-67.
  23. Li L, Luo ZQ, Zhou FW, Feng DD, Guang CX, Zhang CQ, et al. Effect of vasoactive intestinal peptide on pulmonary surfactants phospholipid synthesis in lung explants. Acta Pharmacol Sin 2004;25:1652-8.
  24. Hashimoto S, Kobayashi A, Kooguchi K, Kitamura Y, Onodera H, Nakajima H, et al. Upregulation of two death pathways of perforin/granzyme and FasL/Fas in spetic acute respiratory distress syndrome. Am J Respir Crit Care Med 2000;161:237-43.
  25. Javitt JC. Perspective: The potential role of vasoactive intestinal peptide in treating COVID-19. Authorea 2020.
  26. Raveendran AV, Dhuhli AL, Salim K, Kumar HG. Role of aviptadil in COVID-19. BMH Med J 2021;8:77-83. Available from:>. [Last accessed on 2021 Nov 07].
  27. Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008;32:1289-94.
  28. Prasse A, Zissel G, Lützen N, Schupp J, Schmiedlin R, Gonzalez-Rey E, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 2010;182:540-8.
  29. Jihad Y, Sami S, George Y, Matthew J, Jonathan J. Treatment of sepsis-related acute respiratory distress syndrome with vasoactive intestinal Peptide. Preprints 2020, 2020070453.
  30. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease
  31. J Clin Invest 2020;130:2620-9.
  32. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLoS Pathog 2020;16:e1008536.
  33. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol 2020;11:1446.
  34. Giamarellos-Bourboulis EJ, Nitea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 2020;27:992-1000.e3.
  35. Bouvet M, Debarnot C, Imber I, Selisko B, Snijder EJ, Canard B, et al. In vitro reconstitution of SARS-coronavirus mRNA cap methylation. PLoS Pathog 2010;6:e1000863.
  36. Bollati M, Milani M, Mastrangelo E, Ricagno S, Tedeschi G, Nonnis S, et al. Recognition of RNA cap in the Wesselsbron virus NS5 methyltransferase domain: Implications for RNA-capping mechanisms in Flavivirus. J Mol Biol 2009;385:140-52.
  37. Alnomasy SF, Alotaibi BS, Aldosari ZM, Mujamammi AH, Anand P, Akhtar YA, et al. Inhibitory effects of aviptadil on the SARS-CoV-2 nsp10/nsp16 protein complex. Research Square 2021. DOI: 10.21203/
  38. Youssef JG, Zahiruddin F, Al-Saadi M, Yau S, Goodarzi A, Huang HJ, et al. Brief report: Rapid clinical recovery from critical COVID-19 with respiratory failure in a lung transplant patient treated with intravenous vasoactive intestinal peptide.
  39. Javitt J, Youssef J. Rapid recovery in six patients with COVID-19 respiratory failure after treatment with vasoactive intestinal peptide. preprints 2020, 2020080640. [Doi: 10.20944/preprints202008.0640.v1].
  40. Youssef JG, Zahiruddin F, Al-Saadi M, Yau S, Goodarzi A, Huang HJ, et al. Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide. Preprints 2020, 2020070178 [Doi: 10.20944/preprints202007.0178.v2].
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.